Paper17522506
A randomized, controlled trial of postoperative adjuvant interferon therapy after resection of hepatocellular carcinoma.
Lo CM and 7 others. Ann Surg, 2007. Cited by 198 papers, by iCite.
Cite this record
ConductScience Library. A randomized, controlled trial of postoperative adjuvant interferon therapy after resection of hepatocellular carcinoma. Papers, record 17522506. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/17522506
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics23
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antineoplastic Agents | Major topic |
| Carcinoma, Hepatocellular | Major topic |
| Interferon-alpha | Major topic |
| Liver Neoplasms | Major topic |
| Adult | |
| Aged | |
| Chemotherapy, Adjuvant | |
| Chi-Square Distribution | |
| Combined Modality Therapy | |
| Female | |
| Hepatectomy | |
| Hepatitis B | |
| Humans | |
| Interferon alpha-2 | |
| Male | |
| Middle Aged | |
| Neoplasm Staging | |
| Prognosis | |
| Proportional Hazards Models | |
| Recombinant Proteins | |
| Statistics, Nonparametric | |
| Survival Rate | |
| Treatment Outcome |
Source PubMed
Trials1
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record |
|---|---|---|---|
| NCT01681446 | Adjuvant IFN-α for Patients Underwent Curative Surgery for HCC With a Low miR-26 Expression | Background |
Source ClinicalTrials.gov
Comments and corrections1
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
| Kind | PMID | Title | In Papers |
|---|---|---|---|
| Comment in | 17522507 | Interferon: the magic bullet to prevent hepatocellular carcinoma recurrence after resection? | https://conductscience.org/library/papers/17522507 |
Source PubMed
References33
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 10077043 | Hepatectomy for hepatocellular carcinoma: toward zero hospital deaths. | Ann Surg | 1999 | https://conductscience.org/library/papers/10077043 | PubMed |
| 2 | 8392955 | Incidence and factors associated with intrahepatic recurrence following resection of hepatocellular carcinoma. | Gastroenterology | 1993 | https://conductscience.org/library/papers/8392955 | PubMed |
| 3 | 10869287 | High-dose and long-term therapy with interferon-alfa inhibits tumor growth and recurrence in nude mice bearing human hepatocellular carcinoma xenografts with high metastatic potential. | Hepatology | 2000 | https://conductscience.org/library/papers/10869287 | PubMed |
| 4 | 10051505 | Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection. | Hepatology | 1999 | https://conductscience.org/library/papers/10051505 | PubMed |
| 5 | 11772139 | Peginterferon-alpha-2a (40 kD): a review of its use in the management of chronic hepatitis C. | Drugs | 2001 | https://conductscience.org/library/papers/11772139 | PubMed |
| 6 | 8628336 | Prevention of second primary tumors by an acyclic retinoid, polyprenoic acid, in patients with hepatocellular carcinoma. Hepatoma Prevention Study Group. | N Engl J Med | 1996 | https://conductscience.org/library/papers/8628336 | PubMed |
| 7 | 7539237 | Hepatocellular carcinoma: surgical resection versus surgical resection combined with pre- and post-operative locoregional immunotherapy-chemotherapy. A prospective randomized study. | Anticancer Res | 1995 | https://conductscience.org/library/papers/7539237 | PubMed |
| 8 | 10694562 | Long-term prognosis after resection of hepatocellular carcinoma associated with hepatitis B-related cirrhosis. | J Clin Oncol | 2000 | https://conductscience.org/library/papers/10694562 | PubMed |
| 9 | 8224650 | Multiple hepatocellular carcinomas at the early stage have different clonality. | Gastroenterology | 1993 | https://conductscience.org/library/papers/8224650 | PubMed |
| 10 | 10931448 | Different risk factors and prognosis for early and late intrahepatic recurrence after resection of hepatocellular carcinoma. | Cancer | 2000 | https://conductscience.org/library/papers/10931448 | PubMed |
| 11 | 12644537 | Effects of interferon alpha on vascular endothelial growth factor gene transcription and tumor angiogenesis. | J Natl Cancer Inst | 2003 | https://conductscience.org/library/papers/12644537 | PubMed |
| 12 | 9151912 | Adjuvant chemotherapy with epirubicin and carmofur after radical resection of hepatocellular carcinoma: a prospective randomized study. | Semin Oncol | 1997 | https://conductscience.org/library/papers/9151912 | PubMed |
| 13 | 11413528 | Adjuvant chemotherapy after resection of hepatocellular carcinoma causes deterioration of long-term prognosis in cirrhotic patients: metaanalysis of three randomized controlled trials. | Cancer | 2001 | https://conductscience.org/library/papers/11413528 | PubMed |
| 14 | 12372721 | Neoadjuvant and adjuvant therapy for resectable hepatocellular carcinoma: review of the randomised clinical trials. | Lancet Oncol | 2002 | https://conductscience.org/library/papers/12372721 | PubMed |
| 15 | 8383088 | Recombinant interferon-alpha in inoperable hepatocellular carcinoma: a randomized controlled trial. | Hepatology | 1993 | https://conductscience.org/library/papers/8383088 | PubMed |
| 16 | 8618580 | Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. | N Engl J Med | 1996 | https://conductscience.org/library/papers/8618580 | PubMed |
| 17 | 3019535 | Clonal origin of human hepatoma determined by integration of hepatitis B virus DNA. | Cancer Res | 1986 | https://conductscience.org/library/papers/3019535 | PubMed |
| 18 | 12823597 | Peginterferon alpha-2a (40 kDa): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B. | J Viral Hepat | 2003 | https://conductscience.org/library/papers/12823597 | PubMed |
| 19 | 14716774 | Prospective randomized controlled study of interferon-alpha in preventing hepatocellular carcinoma recurrence after medical ablation therapy for primary tumors. | Cancer | 2004 | https://conductscience.org/library/papers/14716774 | PubMed |
| 20 | 6088019 | Primary liver cancer. An Eastern Cooperative Oncology Group Trial. | Cancer | 1984 | https://conductscience.org/library/papers/6088019 | PubMed |
Cited by89
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 198 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 41312046 | Pegylated Interferon-α-Induced Functional Cure for Special Populations with Chronic Hepatitis B Virus Infection: Current Trends, Challenges and Prospection. | Drug Des Devel Ther | 2025 | https://conductscience.org/library/papers/41312046 | PubMed |
| 39212922 | Hepatocellular Carcinoma: Surgical Management and Evolving Therapies. | Cancer Treat Res | 2024 | https://conductscience.org/library/papers/39212922 | PubMed |
| 38779519 | Adjuvant Therapy for Hepatocellular Carcinoma After Curative Treatment: Several Unanswered Questions. | J Clin Transl Hepatol | 2024 | https://conductscience.org/library/papers/38779519 | PubMed |
| 38733195 | [Research progress on the effect of hepatitis B virus DNA integration on antiviral therapy]. | Zhonghua Gan Zang Bing Za Zhi | 2024 | https://conductscience.org/library/papers/38733195 | PubMed |
| 38622688 | Interferon-α stimulates DExH-box helicase 58 to prevent hepatocyte ferroptosis. | Mil Med Res | 2024 | https://conductscience.org/library/papers/38622688 | PubMed |
| 38188092 | Harmine Hydrochloride Induces G2/M Cell Cycle Arrest and Apoptosis in SK-Hep1 Hepatocellular Carcinoma Cells by Regulating Mitogen-Activated Protein Kinases and the PI3K/AKT Pathway. | Prev Nutr Food Sci | 2023 | https://conductscience.org/library/papers/38188092 | PubMed |
| 38165580 | Interferon therapy improves survival in patients with hepatitis B virus-related hepatocellular carcinoma after curative surgery: a meta-analysis. | Hepatol Int | 2024 | https://conductscience.org/library/papers/38165580 | PubMed |
| 38164272 | Long-Term Survival and Cancer Risk in the Hepatitis C Virus-Infected Patients After Antiviral Treatment: A Nationwide Cohort Study. | J Cancer | 2024 | https://conductscience.org/library/papers/38164272 | PubMed |
| 37958294 | Hepatocellular Carcinoma: Surveillance, Diagnosis, Evaluation and Management. | Cancers (Basel) | 2023 | https://conductscience.org/library/papers/37958294 | PubMed |
| 37901768 | Guidelines for the Diagnosis and Treatment of Primary Liver Cancer (2022 Edition). | Liver Cancer | 2023 | https://conductscience.org/library/papers/37901768 | PubMed |
| 37730533 | Network meta-analysis of adjuvant treatments for patients with hepatocellular carcinoma after curative resection. | BMC Gastroenterol | 2023 | https://conductscience.org/library/papers/37730533 | PubMed |
| 37382760 | Perioperative safety, oncologic outcome, and risk factors of salvage liver resection for initially unresectable hepatocellular carcinoma converted by transarterial chemoembolization plus tyrosine kinase inhibitor and anti-PD-1 antibody: a retrospective multicenter study of 83 patients. | Hepatol Int | 2023 | https://conductscience.org/library/papers/37382760 | PubMed |
| 37139151 | Adjuvant therapy following curative treatments for hepatocellular carcinoma: current dilemmas and prospects. | Front Oncol | 2023 | https://conductscience.org/library/papers/37139151 | PubMed |
| 36968218 | Impact of adjuvant sorafenib treatment after local ablation for HCC in the phase II SORAMIC trial. | JHEP Rep | 2023 | https://conductscience.org/library/papers/36968218 | PubMed |
| 36926237 | Current status and prospect of treatments for recurrent hepatocellular carcinoma. | World J Hepatol | 2023 | https://conductscience.org/library/papers/36926237 | PubMed |
| 36909127 | Human Epidermal Growth Factor Receptor 2 (HER2) Expression by Immunohistochemistry and Its Clinical Significance in Hepatocellular Carcinoma: A Single-Center Analysis. | Cureus | 2023 | https://conductscience.org/library/papers/36909127 | PubMed |
| 36645648 | Adjuvant anti-PD-1 antibody for hepatocellular carcinoma with high recurrence risks after hepatectomy. | Hepatol Int | 2023 | https://conductscience.org/library/papers/36645648 | PubMed |
| 36187393 | Advances in postoperative adjuvant therapy for primary liver cancer. | World J Gastrointest Oncol | 2022 | https://conductscience.org/library/papers/36187393 | PubMed |
| 35459855 | The combination of PD-1 blockade with interferon-α has a synergistic effect on hepatocellular carcinoma. | Cell Mol Immunol | 2022 | https://conductscience.org/library/papers/35459855 | PubMed |
| 35300207 | Postoperative Adjuvant Transarterial Chemoembolization Plus Tyrosine Kinase Inhibitor for Hepatocellular Carcinoma: a Multicentre Retrospective Study. | J Hepatocell Carcinoma | 2022 | https://conductscience.org/library/papers/35300207 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| IFNA2 | 3440 | PubTator's text mining | https://conductscience.org/library/genes/3440 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/17522506
GET https://conductscience.org/api/papers/v1/17522506/references?page=2